293 related articles for article (PubMed ID: 29564871)
1. Long-term treatment of psoriatic patients with adalimumab reduces disease severity and maintains a favorable lipid pattern and a low Atherogenic Index.
Zangrilli A; Bavetta M; Scaramella M; Bianchi L
G Ital Dermatol Venereol; 2018 Apr; 153(2):146-154. PubMed ID: 29564871
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
[TBL] [Abstract][Full Text] [Related]
5. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
6. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.
Paul C; van de Kerkhof P; Puig L; Unnebrink K; Goldblum O; Thaçi D
Eur J Dermatol; 2012; 22(6):762-9. PubMed ID: 23178916
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.
Van den Bosch F; Manger B; Goupille P; McHugh N; Rødevand E; Holck P; van Vollenhoven RF; Leirisalo-Repo M; Fitzgerald O; Kron M; Frank M; Kary S; Kupper H
Ann Rheum Dis; 2010 Feb; 69(2):394-9. PubMed ID: 19815494
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).
Mease PJ; Ory P; Sharp JT; Ritchlin CT; Van den Bosch F; Wellborne F; Birbara C; Thomson GT; Perdok RJ; Medich J; Wong RL; Gladman DD
Ann Rheum Dis; 2009 May; 68(5):702-9. PubMed ID: 18684743
[TBL] [Abstract][Full Text] [Related]
9. Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial.
Tillett W; Egeberg A; Sonkoly E; Gorecki P; Tjärnlund A; Buyze J; Wegner S; McGonagle D
Arthritis Res Ther; 2023 Sep; 25(1):169. PubMed ID: 37715294
[TBL] [Abstract][Full Text] [Related]
10. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
[TBL] [Abstract][Full Text] [Related]
11. A case of psoriatic arthritis, with joint involvement preceding skin involvement, successfully treated with adalimumab (80 mg every other week).
Nanke Y; Kobashigawa T; Sugimoto N; Yamanaka H; Kotake S
Immunol Med; 2019 Jun; 42(2):99-102. PubMed ID: 31446856
[TBL] [Abstract][Full Text] [Related]
12. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
[TBL] [Abstract][Full Text] [Related]
13. Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study.
Chiricozzi A; Zangrilli A; Bavetta M; Bianchi L; Chimenti S; Saraceno R
J Eur Acad Dermatol Venereol; 2017 Feb; 31(2):304-311. PubMed ID: 27324646
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab for the treatment of severe psoriasis and psoriatic arthritis.
Papoutsaki M; Costanzo A; Chimenti MS; Chimenti S
Expert Opin Biol Ther; 2008 Mar; 8(3):363-70. PubMed ID: 18294106
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice.
Khobzey K; Liskova I; Szegedi A; Pavlovsky L; Lunder T; Kingo K; Miljković J; Péč J; Bohinc M; Hojnik M
Acta Dermatovenerol Alp Pannonica Adriat; 2017 Mar; 26(1):11-14. PubMed ID: 28352929
[TBL] [Abstract][Full Text] [Related]
17. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
Kavanaugh A; McInnes I; Mease P; Krueger GG; Gladman D; Gomez-Reino J; Papp K; Zrubek J; Mudivarthy S; Mack M; Visvanathan S; Beutler A
Arthritis Rheum; 2009 Apr; 60(4):976-86. PubMed ID: 19333944
[TBL] [Abstract][Full Text] [Related]
18. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT.
Mease PJ; Heckaman M; Kary S; Kupper H
J Rheumatol; 2013 May; 40(5):647-52. PubMed ID: 23504383
[TBL] [Abstract][Full Text] [Related]
19. Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics.
Asahina A; Umezawa Y; Yanaba K; Nakagawa H
J Dermatol; 2016 Jul; 43(7):779-84. PubMed ID: 26704718
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
Elewski BE; Okun MM; Papp K; Baker CS; Crowley JJ; Guillet G; Sundaram M; Poulin Y; Gu Y; Geng Z; Williams DA; Rich PA
J Am Acad Dermatol; 2018 Jan; 78(1):90-99.e1. PubMed ID: 28993005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
